Revlimid Plus Dexamethasone Versus Standard Treatment for Multiple Myeloma
February 13, 2014
Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses results from a phase III trial that compared lenalidomide (Revlimid) plus dexamethasone versus the standard treatment of melphalan plus prednisone and thalidomide (MPT) in patients with multiple myeloma who are over 65 years old. Durie offers his thoughts regarding the impact of this trial.